Trial Outcomes & Findings for Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT NCT01707004)

NCT ID: NCT01707004

Last Updated: 2019-11-21

Results Overview

Will be analyzed using Kaplan-Meier (KM) method, and OS will be obtained from the KM estimates along with 95% confidence intervals.

• Recruitment status: COMPLETED
• Study phase: PHASE2
• Target enrollment: 20 participants
• Primary outcome timeframe: Day 100
• Results posted on: 2019-11-21

Participant Flow

Recruitment of high risk BMT patients with active disease at time of transplant or very high risk to relapse post-transplant.

Participant milestones

Measure	Decitabine + Bone Marrow Transplant Pre-transplant Decitabine followed by Bone Marrow Transplant.
Overall Study STARTED	20
Overall Study COMPLETED	17
Overall Study NOT COMPLETED	3

Reasons for withdrawal

Measure	Decitabine + Bone Marrow Transplant Pre-transplant Decitabine followed by Bone Marrow Transplant.
Overall Study Physician Decision	3

Baseline Characteristics

17 participants received transplant on study

Baseline characteristics by cohort

Measure	Decitabine + Bone Marrow Transplant n=20 Participants Pre-transplant Decitabine followed by Bone Marrow Transplant.
Age, Categorical <=18 years	0 Participants n=20 Participants
Age, Categorical Between 18 and 65 years	11 Participants n=20 Participants
Age, Categorical >=65 years	9 Participants n=20 Participants
Sex: Female, Male Female	6 Participants n=20 Participants
Sex: Female, Male Male	14 Participants n=20 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=20 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	20 Participants n=20 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=20 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=20 Participants
Race (NIH/OMB) Asian	0 Participants n=20 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=20 Participants
Race (NIH/OMB) Black or African American	0 Participants n=20 Participants
Race (NIH/OMB) White	20 Participants n=20 Participants
Race (NIH/OMB) More than one race	0 Participants n=20 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=20 Participants
Region of Enrollment United States	20 participants n=20 Participants
Donor Type Matched Related	5 Participants n=17 Participants • 17 participants received transplant on study
Donor Type Haplo-identical	12 Participants n=17 Participants • 17 participants received transplant on study
Disease Risk by DRI Low Risk	0 Participants n=20 Participants
Disease Risk by DRI Intermediate Risk	2 Participants n=20 Participants
Disease Risk by DRI High Risk	13 Participants n=20 Participants
Disease Risk by DRI Very High Risk	5 Participants n=20 Participants
HCT-CI Score 0	5 Participants n=20 Participants
HCT-CI Score 1-2	7 Participants n=20 Participants
HCT-CI Score 3+	8 Participants n=20 Participants
Disease Status AML	15 participants n=20 Participants
Disease Status Primary Induction Failure	6 participants n=20 Participants
Disease Status Relapsed Disease	7 participants n=20 Participants
Disease Status CR1 with high risk features	2 participants n=20 Participants
Disease Status MDS	5 participants n=20 Participants

PRIMARY outcome

Timeframe: Day 100

Population: (2 patients did not receive a transplant due to infectious complications, 1 patient received transplant off protocol)

Will be analyzed using Kaplan-Meier (KM) method, and OS will be obtained from the KM estimates along with 95% confidence intervals.

Outcome measures

Measure	Decitabine + Bone Marrow Transplant n=17 Participants Pre-transplant Decitabine followed by Bone Marrow Transplant.
Overall Survival (OS)	64.7 percentage of participants Interval 45.5 to 91.9

SECONDARY outcome

Timeframe: Up to 1 year

Defined as achieving an absolute neutrophil count (ANC) greater than or equal to 500/ul for three consecutive measurements on different days. Will be summarized with mean and standard deviation or median and interquartile range, and the change will be tested using a one-sample paired t-test at a two-tailed significance level of 0.05.

Outcome measures

Measure	Decitabine + Bone Marrow Transplant n=17 Participants Pre-transplant Decitabine followed by Bone Marrow Transplant.
Time to Neutrophil Recovery	16 days Interval 16.0 to 19.0

SECONDARY outcome

Timeframe: Up to day 30

Platelet recovery is defined as the first day of a platelet count greater than 20,000/mm^3 with no platelet transfusions. Will be summarized with mean and standard deviation or median and interquartile range, and the change will be tested using a one-sample paired t-test at a two-tailed significance level of 0.05.

Outcome measures

Measure	Decitabine + Bone Marrow Transplant n=17 Participants Pre-transplant Decitabine followed by Bone Marrow Transplant.
Percentage of Participants With Platelet Recovery by Day 30	58 percentage with plt engraftment, day 30 Interval 31.3 to 78.4

SECONDARY outcome

Timeframe: Day 30

Defined as less than 5% donor chimerism in the cluster of differentiation (CD)3 and CD33 selected cell populations at any time after transplantation. Will be analyzed using KM method.

Outcome measures

Measure	Decitabine + Bone Marrow Transplant n=17 Participants Pre-transplant Decitabine followed by Bone Marrow Transplant.
Number of Participants With Primary Graft Failure	0 Participants

SECONDARY outcome

Timeframe: Day 100

Determined by the standard bone marrow transplant (BMT) Clinical Trials Network criteria (BMTCTN). Will be analyzed using KM method, a Graft versus Host Disease (GVHD) grade III-IV will be obtained from the KM estimates along with 95% confidence intervals.

Outcome measures

Measure	Decitabine + Bone Marrow Transplant n=17 Participants Pre-transplant Decitabine followed by Bone Marrow Transplant.
Cumulative Incidence of Grade III-IV Acute GVHD	27.8 percentage of participants Interval 8.0 to 52.3

SECONDARY outcome

Timeframe: Up to 1 year

Will be summarized with a proportion and a 95% confidence interval.

Outcome measures

Measure	Decitabine + Bone Marrow Transplant n=17 Participants Pre-transplant Decitabine followed by Bone Marrow Transplant.
Cumulative Incidence of Chronic GVHD According to BMTCTN	40.7 percentage Interval 6.9 to 74.0

SECONDARY outcome

Timeframe: Up to 1 year

Outcome measures

Measure	Decitabine + Bone Marrow Transplant n=17 Participants Pre-transplant Decitabine followed by Bone Marrow Transplant.
Number of Participants With Complete Remission After Transplantation	14 Participants

SECONDARY outcome

Timeframe: Up to 1 year

Outcome measures

Measure	Decitabine + Bone Marrow Transplant n=17 Participants Pre-transplant Decitabine followed by Bone Marrow Transplant.
Progression Free Survival	141 days Interval 69.0 to 492.0

Adverse Events

Decitabine (N=20)

Serious events: 0 serious events

Other events: 20 other events

Deaths: 15 deaths

Transplant (N=17)

Serious events: 12 serious events

Other events: 17 other events

Deaths: 13 deaths

Serious adverse events

Measure	Decitabine (N=20) n=20 participants at risk Pre-transplant Decitabine	Transplant (N=17) n=17 participants at risk Pre-transplant Decitabine followed by Bone Marrow Transplant
Gastrointestinal disorders Abdominal pain	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Gastrointestinal disorders Diarrhea	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Immune system disorders Immune system disorders - Other, specify	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Infections and infestations Anorectal infection	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Infections and infestations Encephalitis infection	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Infections and infestations Enterocolitis infectious	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Infections and infestations Infections and infestations - Other, specify	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Infections and infestations Sepsis	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Nervous system disorders Syncope	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Psychiatric disorders Delirium	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.

Other adverse events

Measure	Decitabine (N=20) n=20 participants at risk Pre-transplant Decitabine	Transplant (N=17) n=17 participants at risk Pre-transplant Decitabine followed by Bone Marrow Transplant
Blood and lymphatic system disorders Anemia	100.0% 20/20 • Number of events 65 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	100.0% 17/17 • Number of events 202 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Blood and lymphatic system disorders Febrile Neutropenia	10.0% 2/20 • Number of events 3 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	35.3% 6/17 • Number of events 7 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Investigations Platelet Count Decreased	90.0% 18/20 • Number of events 57 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	100.0% 17/17 • Number of events 139 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Investigations White Blood Cell Decreased	85.0% 17/20 • Number of events 30 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	100.0% 17/17 • Number of events 105 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Investigations Neutrophil Count Decreased	65.0% 13/20 • Number of events 30 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	100.0% 17/17 • Number of events 89 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Investigations Lymphocyte count decreased	80.0% 16/20 • Number of events 30 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	94.1% 16/17 • Number of events 141 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Investigations Aspartate aminotransferase increased	10.0% 2/20 • Number of events 3 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	88.2% 15/17 • Number of events 31 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Investigations Alanine aminotransferase increased	10.0% 2/20 • Number of events 2 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	70.6% 12/17 • Number of events 29 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Investigations Alkaline phosphatase increased	25.0% 5/20 • Number of events 5 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	64.7% 11/17 • Number of events 22 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Investigations Creatinine increased	15.0% 3/20 • Number of events 3 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	70.6% 12/17 • Number of events 26 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Investigations Weight loss	10.0% 2/20 • Number of events 4 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	64.7% 11/17 • Number of events 42 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Investigations GGT increased	5.0% 1/20 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	70.6% 12/17 • Number of events 26 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Investigations Blood bilirubin increased	5.0% 1/20 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	58.8% 10/17 • Number of events 19 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Investigations Weight gain	5.0% 1/20 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	35.3% 6/17 • Number of events 12 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Investigations INR increased	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	29.4% 5/17 • Number of events 6 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Investigations Electrocardiogram QT corrected interval prolonged	5.0% 1/20 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Investigations Lymphocyte count increased	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	11.8% 2/17 • Number of events 3 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Investigations CD4 lymphocytes decreased	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Investigations Cholesterol high	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 2 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Metabolism and nutrition disorders Anorexia	20.0% 4/20 • Number of events 4 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	100.0% 17/17 • Number of events 37 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Metabolism and nutrition disorders Hypoalbuminemia	20.0% 4/20 • Number of events 6 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	100.0% 17/17 • Number of events 80 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Metabolism and nutrition disorders Hypokalemia	30.0% 6/20 • Number of events 12 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	94.1% 16/17 • Number of events 76 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Metabolism and nutrition disorders Hypomagnesemia	25.0% 5/20 • Number of events 5 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	100.0% 17/17 • Number of events 135 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Metabolism and nutrition disorders Hyponatremia	5.0% 1/20 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	70.6% 12/17 • Number of events 28 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Metabolism and nutrition disorders Hypernatremia	5.0% 1/20 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	64.7% 11/17 • Number of events 37 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Metabolism and nutrition disorders Hypophosphatemia	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	70.6% 12/17 • Number of events 25 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Metabolism and nutrition disorders Hypocalcemia	10.0% 2/20 • Number of events 2 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	52.9% 9/17 • Number of events 22 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Metabolism and nutrition disorders Dehydration	10.0% 2/20 • Number of events 2 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	41.2% 7/17 • Number of events 13 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Metabolism and nutrition disorders Hyperkalemia	5.0% 1/20 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	41.2% 7/17 • Number of events 11 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Metabolism and nutrition disorders Hypermagnesemia	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	47.1% 8/17 • Number of events 13 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Metabolism and nutrition disorders Hyperglycemia	10.0% 2/20 • Number of events 2 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	35.3% 6/17 • Number of events 15 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Metabolism and nutrition disorders Hypertriglyceridemia	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	41.2% 7/17 • Number of events 9 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Metabolism and nutrition disorders Hypercalcemia	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	23.5% 4/17 • Number of events 4 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Metabolism and nutrition disorders Metabolism and nutrition disorders - Other, specify	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
General disorders Fatigue	55.0% 11/20 • Number of events 13 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	76.5% 13/17 • Number of events 39 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
General disorders Edema limbs	10.0% 2/20 • Number of events 2 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	76.5% 13/17 • Number of events 28 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
General disorders Chills	10.0% 2/20 • Number of events 2 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	41.2% 7/17 • Number of events 11 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
General disorders Fever	10.0% 2/20 • Number of events 2 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	17.6% 3/17 • Number of events 5 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
General disorders Pain	5.0% 1/20 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	17.6% 3/17 • Number of events 3 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
General disorders Non-cardiac chest pain	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	17.6% 3/17 • Number of events 4 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
General disorders Facial pain	5.0% 1/20 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
General disorders Edema face	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
General disorders Infusion related reaction	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	17.6% 3/17 • Number of events 3 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
General disorders Localized edema	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
General disorders Malaise	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Gastrointestinal disorders Nausea	45.0% 9/20 • Number of events 12 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	88.2% 15/17 • Number of events 39 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Gastrointestinal disorders Mucositis oral	5.0% 1/20 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	100.0% 17/17 • Number of events 49 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Gastrointestinal disorders Diarrhea	20.0% 4/20 • Number of events 4 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	88.2% 15/17 • Number of events 103 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Gastrointestinal disorders Vomiting	10.0% 2/20 • Number of events 2 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	76.5% 13/17 • Number of events 43 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Gastrointestinal disorders Abdominal pain	10.0% 2/20 • Number of events 2 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	64.7% 11/17 • Number of events 22 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Gastrointestinal disorders Constipation	10.0% 2/20 • Number of events 2 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	58.8% 10/17 • Number of events 16 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Gastrointestinal disorders Dry mouth	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	58.8% 10/17 • Number of events 10 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Gastrointestinal disorders Dyspepsia	5.0% 1/20 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	29.4% 5/17 • Number of events 5 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Gastrointestinal disorders Hemorrhoids	5.0% 1/20 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	23.5% 4/17 • Number of events 6 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Gastrointestinal disorders Bloating	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	17.6% 3/17 • Number of events 3 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Gastrointestinal disorders Dysphagia	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	17.6% 3/17 • Number of events 4 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Gastrointestinal disorders Esophagitis	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	11.8% 2/17 • Number of events 4 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Gastrointestinal disorders Gastroesophageal reflux disease	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	11.8% 2/17 • Number of events 2 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Gastrointestinal disorders Lower gastrointestinal hemorrhage	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	11.8% 2/17 • Number of events 3 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Gastrointestinal disorders Rectal pain	5.0% 1/20 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Gastrointestinal disorders Abdominal distension	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 2 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Gastrointestinal disorders Ascites	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Gastrointestinal disorders Enterocolitis	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 2 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Gastrointestinal disorders Gastrointestinal disorders - Other, specify	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Gastrointestinal disorders Hemorrhoidal hemorrhage	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Gastrointestinal disorders Lip pain	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Gastrointestinal disorders Oral hemorrhage	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Gastrointestinal disorders Rectal hemorrhage	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	52.9% 9/17 • Number of events 11 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Respiratory, thoracic and mediastinal disorders Dyspnea	15.0% 3/20 • Number of events 3 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	29.4% 5/17 • Number of events 9 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Respiratory, thoracic and mediastinal disorders Sore throat	5.0% 1/20 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	35.3% 6/17 • Number of events 14 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Respiratory, thoracic and mediastinal disorders Epistaxis	5.0% 1/20 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	29.4% 5/17 • Number of events 10 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Respiratory, thoracic and mediastinal disorders Hypoxia	5.0% 1/20 • Number of events 2 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	23.5% 4/17 • Number of events 9 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Respiratory, thoracic and mediastinal disorders Pleural effusion	5.0% 1/20 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	17.6% 3/17 • Number of events 5 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Respiratory, thoracic and mediastinal disorders Hiccups	5.0% 1/20 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	11.8% 2/17 • Number of events 2 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	11.8% 2/17 • Number of events 5 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	11.8% 2/17 • Number of events 2 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Respiratory, thoracic and mediastinal disorders Wheezing	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	11.8% 2/17 • Number of events 2 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Respiratory, thoracic and mediastinal disorders Apnea	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Respiratory, thoracic and mediastinal disorders Aspiration	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Respiratory, thoracic and mediastinal disorders Laryngeal mucositis	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Respiratory, thoracic and mediastinal disorders Nasal congestion	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Respiratory, thoracic and mediastinal disorders Pharyngeal mucositis	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Respiratory, thoracic and mediastinal disorders Pleuritic pain	5.0% 1/20 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 5 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Respiratory, thoracic and mediastinal disorders Productive cough	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Skin and subcutaneous tissue disorders Rash maculo-papular	5.0% 1/20 • Number of events 2 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	58.8% 10/17 • Number of events 19 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Skin and subcutaneous tissue disorders Dry skin	10.0% 2/20 • Number of events 2 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	52.9% 9/17 • Number of events 10 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Skin and subcutaneous tissue disorders Skin and subcutaneous tissue disorders - Other, specify	10.0% 2/20 • Number of events 2 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	52.9% 9/17 • Number of events 11 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Skin and subcutaneous tissue disorders Pruritus	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	23.5% 4/17 • Number of events 4 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Skin and subcutaneous tissue disorders Pain of skin	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	17.6% 3/17 • Number of events 9 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Skin and subcutaneous tissue disorders Palmar-plantar erythrodysesthesia syndrome	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	11.8% 2/17 • Number of events 2 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Skin and subcutaneous tissue disorders Skin ulceration	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	11.8% 2/17 • Number of events 2 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Skin and subcutaneous tissue disorders Alopecia	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Skin and subcutaneous tissue disorders Rash acneiform	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Skin and subcutaneous tissue disorders Skin hyperpigmentation	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Infections and infestations Infections and infestations - Other, specify	20.0% 4/20 • Number of events 4 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	70.6% 12/17 • Number of events 20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Infections and infestations Lung infection	15.0% 3/20 • Number of events 5 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	23.5% 4/17 • Number of events 4 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Infections and infestations Urinary tract infection	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	23.5% 4/17 • Number of events 6 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Infections and infestations Mucosal infection	5.0% 1/20 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Infections and infestations Anorectal infection	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Infections and infestations Catheter related infection	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Infections and infestations Encephalitis infection	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 2 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Infections and infestations Enterocolitis infectious	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Infections and infestations Skin infection	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Infections and infestations Upper respiratory infection	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 2 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Musculoskeletal and connective tissue disorders Generalized muscle weakness	20.0% 4/20 • Number of events 4 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	41.2% 7/17 • Number of events 18 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Musculoskeletal and connective tissue disorders Back pain	5.0% 1/20 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	29.4% 5/17 • Number of events 5 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Musculoskeletal and connective tissue disorders Bone pain	15.0% 3/20 • Number of events 3 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	17.6% 3/17 • Number of events 5 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Musculoskeletal and connective tissue disorders Myalgia	5.0% 1/20 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Musculoskeletal and connective tissue disorders Arthralgia	5.0% 1/20 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	0.00% 0/17 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Musculoskeletal and connective tissue disorders Flank pain	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Vascular disorders Hypertension	35.0% 7/20 • Number of events 15 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	70.6% 12/17 • Number of events 88 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Vascular disorders Hypotension	20.0% 4/20 • Number of events 4 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	52.9% 9/17 • Number of events 20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Vascular disorders Flushing	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	11.8% 2/17 • Number of events 4 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Vascular disorders Hematoma	5.0% 1/20 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	11.8% 2/17 • Number of events 2 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Vascular disorders Thromboembolic event	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	11.8% 2/17 • Number of events 2 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Vascular disorders Hot flashes	5.0% 1/20 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Nervous system disorders Dysgeusia	5.0% 1/20 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	64.7% 11/17 • Number of events 11 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Nervous system disorders Dizziness	10.0% 2/20 • Number of events 3 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	47.1% 8/17 • Number of events 14 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Nervous system disorders Headache	15.0% 3/20 • Number of events 4 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	35.3% 6/17 • Number of events 10 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Nervous system disorders Tremor	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	23.5% 4/17 • Number of events 5 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Nervous system disorders Peripheral sensory neuropathy	5.0% 1/20 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Nervous system disorders Presyncope	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	11.8% 2/17 • Number of events 2 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Nervous system disorders Syncope	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Renal and urinary disorders Hematuria	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	29.4% 5/17 • Number of events 10 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Renal and urinary disorders Proteinuria	5.0% 1/20 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	17.6% 3/17 • Number of events 7 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Renal and urinary disorders Renal and urinary disorders - Other, specify	5.0% 1/20 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	17.6% 3/17 • Number of events 3 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Renal and urinary disorders Acute kidney injury	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	17.6% 3/17 • Number of events 6 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Renal and urinary disorders Cystitis noninfective	5.0% 1/20 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	11.8% 2/17 • Number of events 2 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Renal and urinary disorders Urinary frequency	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	17.6% 3/17 • Number of events 3 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Renal and urinary disorders Urinary tract pain	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	17.6% 3/17 • Number of events 3 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Renal and urinary disorders Hemoglobinuria	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	11.8% 2/17 • Number of events 2 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Renal and urinary disorders Urinary incontinence	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	11.8% 2/17 • Number of events 3 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Renal and urinary disorders Chronic kidney disease	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 2 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Renal and urinary disorders Urinary urgency	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Renal and urinary disorders Urine discoloration	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Cardiac disorders Sinus tachycardia	30.0% 6/20 • Number of events 8 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	64.7% 11/17 • Number of events 30 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Cardiac disorders Atrial fibrillation	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Cardiac disorders Cardiac disorders - Other, specify	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Cardiac disorders Palpitations	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 2 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Cardiac disorders Sinus bradycardia	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Psychiatric disorders Confusion	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	35.3% 6/17 • Number of events 11 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Psychiatric disorders Insomnia	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	23.5% 4/17 • Number of events 5 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Psychiatric disorders Anxiety	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	17.6% 3/17 • Number of events 3 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Psychiatric disorders Depression	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	11.8% 2/17 • Number of events 4 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Psychiatric disorders Delirium	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 3 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Eye disorders Dry eye	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	23.5% 4/17 • Number of events 5 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Eye disorders Eye disorders - Other, specify	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	17.6% 3/17 • Number of events 3 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Eye disorders Conjunctivitis	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	11.8% 2/17 • Number of events 2 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Eye disorders Cataract	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Eye disorders Photophobia	5.0% 1/20 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	0.00% 0/17 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Immune system disorders Immune system disorders - Other, specify	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	35.3% 6/17 • Number of events 11 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Immune system disorders Allergic reaction	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Injury, poisoning and procedural complications Bruising	5.0% 1/20 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	11.8% 2/17 • Number of events 2 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Injury, poisoning and procedural complications Fall	5.0% 1/20 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Injury, poisoning and procedural complications Vascular access complication	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Reproductive system and breast disorders Breast pain	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Reproductive system and breast disorders Genital edema	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Reproductive system and breast disorders Gynecomastia	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Reproductive system and breast disorders Pelvic pain	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	11.8% 2/17 • Number of events 3 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Ear and labyrinth disorders Ear pain	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.
Ear and labyrinth disorders Hearing impaired	0.00% 0/20 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.	5.9% 1/17 • Number of events 1 • Adverse Events (AEs) data were collected from registration to 1 year post-transplant. AEs were assessed at regularly scheduled follow up visits where physical exams and labs were performed. AEs reported here include grade 3-5 and adverse events that were not related to the disease state. AEs are reported for all participants who received Decitabine, 17 (+ 1 off protocol) participants who received the transplant.

Additional Information

Aric Hall

UW Carbone Cancer Center

Phone: 608-262-1604

Email: achall@medicine.wisc.edu

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place